Covered recipient · General Payments record
GARY C STEVEN
Allopathic & Osteopathic Physicians Allergy & Immunology Allergy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$29,256.67
110 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,019.00 | 14 |
| Consulting Fee | $6,911.00 | 3 |
| Food and Beverage | $1,982.56 | 91 |
| Travel and Lodging | $344.11 | 2 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $9,358.18 | 11 |
| GlaxoSmithKline, LLC. | $8,328.13 | 18 |
| Regeneron Healthcare Solutions, Inc. | $4,770.08 | 10 |
| OptiNose US, Inc. | $4,116.16 | 13 |
| AstraZeneca Pharmaceuticals LP | $1,399.80 | 15 |
| Shionogi Inc | $427.47 | 6 |
| ALK-Abello, Inc | $238.81 | 5 |
| Teva Pharmaceuticals USA, Inc. | $148.75 | 6 |
| Covis Pharma GmbH | $103.23 | 6 |
| Mylan Specialty L.P. | $57.97 | 3 |
| Grifols USA, LLC | $54.94 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $54.29 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $44.96 | 2 |
| Genentech USA, Inc. | $39.67 | 2 |
| PFIZER INC. | $31.51 | 2 |
| Novartis Pharmaceuticals Corporation | $30.23 | 2 |
| Octapharma USA, Inc. | $24.71 | 1 |
| Circassia Pharmaceuticals Inc | $15.30 | 1 |
| kaleo, Inc. | $12.48 | 1 |
Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GARY C STEVEN
NPI 1972530699 · CMS profile ID 134979
Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy
GREENFIELD, WI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972530699?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GARY C STEVEN, NPI 1972530699, CMS profile ID 134979. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972530699?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). GARY C STEVEN, NPI 1972530699, CMS profile ID 134979. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972530699?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- GARY C STEVEN, NPI 1972530699, CMS profile ID 134979, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1972530699?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
110 matching records · $29,256.67 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 110.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $12.22 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738735113 | CMS |
| GlaxoSmithKline, LLC. | $2.08 | 05/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738503139 | CMS |
| GlaxoSmithKline, LLC. | $17.16 | 05/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738592833 | CMS |
| GlaxoSmithKline, LLC. | $3,250.00 | 05/08/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738587175 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.00 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736382243 | CMS |
| GENZYME CORPORATION | $21.11 | 04/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744130243 | CMS |
| Covis Pharma GmbH | $20.77 | 04/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753245729 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.14 | 04/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736413421 | CMS |
| Genentech USA, Inc. | $16.40 | 04/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743015250 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 04/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736368545 | CMS |
| OptiNose US, Inc. | $17.24 | 04/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737165107 | CMS |
| Teva Pharmaceuticals USA, Inc. | $12.30 | 04/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749484367 | CMS |
| Circassia Pharmaceuticals Inc | $15.30 | 03/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746985533 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.53 | 03/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735796291 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,843.00 | 03/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724459145 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.49 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720446749 | CMS |
| GENZYME CORPORATION | $15.00 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744130219 | CMS |
| GENZYME CORPORATION | $2,882.00 | 03/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744130221 | CMS |
| OptiNose US, Inc. | $3.24 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737165101 | CMS |
| Regeneron Healthcare Solutions, Inc. | $144.11 | 03/07/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724459141 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.27 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726906753 | CMS |
| Regeneron Healthcare Solutions, Inc. | $9.98 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726906755 | CMS |
| Regeneron Healthcare Solutions, Inc. | $67.50 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726906757 | CMS |
| Regeneron Healthcare Solutions, Inc. | $10.56 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726906759 | CMS |
| Regeneron Healthcare Solutions, Inc. | $52.20 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726906761 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 03/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738697035 | CMS |
| Mylan Specialty L.P. | $17.93 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751409549 | CMS |
| Teva Pharmaceuticals USA, Inc. | $15.37 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749469609 | CMS |
| OptiNose US, Inc. | $1,750.00 | 02/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737165129 | CMS |
| Optinose US, Inc. | $15.86 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737165133 | CMS |
| Grifols USA, LLC | $18.42 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750408155 | CMS |
| OptiNose US, Inc. | $3.50 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737165099 | CMS |
| Teva Pharmaceuticals USA, Inc. | $71.63 | 02/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749470767 | CMS |
| Covis Pharma GmbH | $14.69 | 02/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753245719 | CMS |
| GlaxoSmithKline, LLC. | $124.44 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738607593 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.86 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747308047 | CMS |
| kaleo, Inc. | $12.48 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 733180477 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.47 | 02/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736439109 | CMS |
| GENZYME CORPORATION | $15.61 | 02/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744130237 | CMS |
| Novartis Pharmaceuticals Corporation | $15.76 | 02/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726148055 | CMS |
| Shionogi Inc | $19.74 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750203409 | CMS |
| Shionogi Inc | $17.11 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750203411 | CMS |
| Shionogi Inc | $46.06 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750203413 | CMS |
| Shionogi Inc | $19.74 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750203415 | CMS |
| Shionogi Inc | $200.00 | 02/05/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750203329 | CMS |
| Shionogi Inc | $124.82 | 02/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750203407 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.98 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724459139 | CMS |
| OptiNose US, Inc. | $18.41 | 02/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737165085 | CMS |
| ALK-Abello, Inc | $9.49 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748135313 | CMS |
| GlaxoSmithKline, LLC. | $13.22 | 01/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738711301 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,269,262.08 | 66 |
| PY2024 | Principal investigator | $725,462.16 | 283 |
| PY2023 | Principal investigator | $550,202.52 | 180 |
| PY2022 | Recipient | $2,029.47 | 3 |
| PY2022 | Principal investigator | $729,811.58 | 120 |
| PY2021 | Principal investigator | $502,176.99 | 107 |
| PY2020 | Principal investigator | $566,337.88 | 64 |
| PY2019 | Principal investigator | $664,801.82 | 107 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
66 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $636.18 | 12/11/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244045968 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $63,364.00 | 12/01/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190307727 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,546.97 | 12/01/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045948 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,614.55 | 11/25/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185553623 |
| Principal investigator 1 | Genentech, Inc. | $7,033.00 | 11/21/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571654 |
| Principal investigator 1 | Genentech, Inc. | $5,085.00 | 11/21/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571658 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $143.92 | 11/14/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045790 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,639.94 | 11/13/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046134 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,000.00 | 10/22/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185553599 |
| Principal investigator 1 | Genentech, Inc. | $2,034.00 | 10/02/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571650 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,596.65 | 09/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046132 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 09/04/2025 | Non-covered Recipient Entity ALLERGY ASTHMA & SINUS CENTER SC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192152451 |
| Principal investigator 1 | Genentech, Inc. | $3,051.00 | 09/02/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571642 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $686.66 | 08/27/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046242 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,096.86 | 08/20/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID) | No dispute reported | 06/30/2026 | 1185553625 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,003.76 | 08/19/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046172 |
| Principal investigator 1 | Genentech, Inc. | $9,067.00 | 08/12/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571646 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,908.80 | 08/01/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046240 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $357.57 | 07/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046174 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $636.18 | 07/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046176 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,554.07 | 07/23/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185553601 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $47,571.74 | 07/10/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185553619 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $52,532.41 | 06/27/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185553617 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,450.00 | 06/25/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185553607 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,912.30 | 06/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046178 |
| Principal investigator 1 | Genentech, Inc. | $4,068.00 | 06/17/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571637 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,042.41 | 05/21/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT | No dispute reported | 06/30/2026 | 1185553609 |
| Principal investigator 1 | Genentech, Inc. | $8,050.00 | 05/20/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571624 |
| Principal investigator 1 | Genentech, Inc. | $3,051.00 | 05/20/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571629 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,847.00 | 05/16/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046424 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $162,361.76 | 05/08/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185553595 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $378.56 | 05/08/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046362 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $87,715.98 | 05/01/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185553635 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $23.76 | 04/21/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045592 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $54.00 | 04/21/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045594 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13.66 | 04/21/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045596 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $45.00 | 04/21/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045598 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $28.00 | 04/21/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045600 |
| Principal investigator 1 | Genentech, Inc. | $2,034.00 | 04/15/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571632 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,027.09 | 04/03/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185553611 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,530.10 | 03/28/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185553631 |
| Principal investigator 1 | Eli Lilly and Company | $555.00 | 03/20/2025 | Non-covered Recipient Entity MEETING PROTOCOL WORLDWIDE LP | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187884548 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,280.00 | 03/06/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185553613 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $105,663.20 | 03/05/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185553627 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 03/05/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046422 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,350.37 | 03/04/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185553621 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,537.50 | 03/04/2025 | Non-covered Recipient Entity Allergy Asthma And Sinus Center | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1226138379 |
| Principal investigator 1 | AstraZeneca UK Limited | $17,201.05 | 02/27/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185553605 |
| Principal investigator 1 | Genentech, Inc. | $7,842.00 | 02/25/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211571607 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,690.27 | 02/24/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185553629 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046066 |
| Principal investigator 1 | Genentech, Inc. | $7,248.00 | 02/18/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211571611 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,900.00 | 02/13/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046364 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,897.56 | 02/13/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046366 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 02/13/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046368 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $717.00 | 02/07/2025 | Non-covered Recipient Entity ALLERGY ASTHMA & SINUS CENTER SC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192152460 |
| Principal investigator 1 | Genentech, Inc. | $1,095.00 | 02/06/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211571615 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $32,434.11 | 02/05/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185553615 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $215.88 | 01/31/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046038 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $49,256.69 | 01/29/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185553603 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $59,400.08 | 01/23/2025 | Non-covered Recipient Entity ALLERGY ASTHMA AND SINUS CENTER GREENFIELD | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185553597 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $253,079.12 | 01/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185553633 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,995.00 | 01/13/2025 | Non-covered Recipient Entity ALLERGY ASTHMA & SINUS CENTER SC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192152456 |
| Principal investigator 1 | Eli Lilly and Company | $104,335.00 | 01/08/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187878019 |
| Principal investigator 1 | Genentech, Inc. | $6,111.00 | 01/02/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211571619 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,460.77 | 01/01/2025 | Non-covered Recipient Entity ALLERGY ASTHMA SINUS CENTER | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190307729 |